These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23570538)

  • 1. The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis.
    ; ; Buckingham BA; Beck RW; Ruedy KJ; Cheng P; Kollman C; Weinzimer SA; DiMeglio LA; Bremer AA; Slover R; Cantwell M
    Diabetes Technol Ther; 2013 May; 15(5):401-8. PubMed ID: 23570538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes.
    Buckingham B; Beck RW; Ruedy KJ; Cheng P; Kollman C; Weinzimer SA; DiMeglio LA; Bremer AA; Slover R; Tamborlane WV; ;
    Diabetes Care; 2013 Dec; 36(12):4030-5. PubMed ID: 24130350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia.
    Anderson SM; Buckingham BA; Breton MD; Robic JL; Barnett CL; Wakeman CA; Oliveri MC; Brown SA; Ly TT; Clinton PK; Hsu LJ; Kingman RS; Norlander LM; Loebner SE; Reuschel-DiVirglio S; Kovatchev BP
    Diabetes Technol Ther; 2019 Jun; 21(6):356-363. PubMed ID: 31095423
    [No Abstract]   [Full Text] [Related]  

  • 4. Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial.
    Stewart ZA; Wilinska ME; Hartnell S; O'Neil LK; Rayman G; Scott EM; Barnard K; Farrington C; Hovorka R; Murphy HR
    Diabetes Care; 2018 Jul; 41(7):1391-1399. PubMed ID: 29535135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
    Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
    Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial.
    Nimri R; Muller I; Atlas E; Miller S; Fogel A; Bratina N; Kordonouri O; Battelino T; Danne T; Phillip M
    Diabetes Care; 2014 Nov; 37(11):3025-32. PubMed ID: 25078901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
    Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
    Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multinight "bedside" closed-loop control for patients with type 1 diabetes.
    Brown SA; Kovatchev BP; Breton MD; Anderson SM; Keith-Hynes P; Patek SD; Jiang B; Ben Brahim N; Vereshchetin P; Bruttomesso D; Avogaro A; Del Favero S; Boscari F; Galasso S; Visentin R; Monaro M; Cobelli C
    Diabetes Technol Ther; 2015 Mar; 17(3):203-9. PubMed ID: 25594434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MD-Logic overnight type 1 diabetes control in home settings: A multicentre, multinational, single blind randomized trial.
    Nimri R; Bratina N; Kordonouri O; Avbelj Stefanija M; Fath M; Biester T; Muller I; Atlas E; Miller S; Fogel A; Phillip M; Danne T; Battelino T
    Diabetes Obes Metab; 2017 Apr; 19(4):553-561. PubMed ID: 27981804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
    Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
    Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manual Closed-Loop Insulin Delivery Using a Saddle Point Model Predictive Control Algorithm: Results of a Crossover Randomized Overnight Study.
    Guilhem I; Penet M; Paillard A; Carpentier M; Esvant A; Lefebvre MA; Poirier JY
    J Diabetes Sci Technol; 2017 Sep; 11(5):1007-1014. PubMed ID: 28677416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral Patterns and Associations with Glucose Control During 12-Week Randomized Free-Living Clinical Trial of Day and Night Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes.
    Emami A; Willinska ME; Thabit H; Leelarathna L; Hartnell S; Dellweg S; Benesch C; Mader JK; Holzer M; Kojzar H; Pieber TR; Arnolds S; Evans ML; Hovorka R
    Diabetes Technol Ther; 2017 Jul; 19(7):433-437. PubMed ID: 28463010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study.
    Sharifi A; De Bock MI; Jayawardene D; Loh MM; Horsburgh JC; Berthold CL; Paramalingam N; Bach LA; Colman PG; Davis EA; Grosman B; Hendrieckx C; Jenkins AJ; Kumareswaran K; Kurtz N; Kyoong A; MacIsaac RJ; Speight J; Trawley S; Ward GM; Roy A; Jones TW; O'Neal DN
    Diabetes Technol Ther; 2016 Dec; 18(12):772-783. PubMed ID: 27835037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.
    Ly TT; Weinzimer SA; Maahs DM; Sherr JL; Roy A; Grosman B; Cantwell M; Kurtz N; Carria L; Messer L; von Eyben R; Buckingham BA
    Pediatr Diabetes; 2017 Aug; 18(5):348-355. PubMed ID: 27191182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multinational Home Use of Closed-Loop Control Is Safe and Effective.
    Anderson SM; Raghinaru D; Pinsker JE; Boscari F; Renard E; Buckingham BA; Nimri R; Doyle FJ; Brown SA; Keith-Hynes P; Breton MD; Chernavvsky D; Bevier WC; Bradley PK; Bruttomesso D; Del Favero S; Calore R; Cobelli C; Avogaro A; Farret A; Place J; Ly TT; Shanmugham S; Phillip M; Dassau E; Dasanayake IS; Kollman C; Lum JW; Beck RW; Kovatchev B;
    Diabetes Care; 2016 Jul; 39(7):1143-50. PubMed ID: 27208316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp.
    Ly TT; Roy A; Grosman B; Shin J; Campbell A; Monirabbasi S; Liang B; von Eyben R; Shanmugham S; Clinton P; Buckingham BA
    Diabetes Care; 2015 Jul; 38(7):1205-11. PubMed ID: 26049550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study.
    Leelarathna L; Dellweg S; Mader JK; Allen JM; Benesch C; Doll W; Ellmerer M; Hartnell S; Heinemann L; Kojzar H; Michalewski L; Nodale M; Thabit H; Wilinska ME; Pieber TR; Arnolds S; Evans ML; Hovorka R;
    Diabetes Care; 2014 Jul; 37(7):1931-7. PubMed ID: 24963110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.